BioLineRx And Hemispherian Present Two Posters Featuring GLIX1 At 31st Society For Neuro-Oncology Annual Meeting
Benzinga Newsdesk 4 days ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
- Fourth cohort initiated in ongoing Phase 1/2a study of GLIX1; remaining cohorts to include patients in window-of-opportunity setting -- GLIX1 demonstrated robust, dose-dependent antitumor activity in multiple GBM
- Fourth cohort initiated in ongoing Phase 1/2a study of GLIX1; remaining cohorts to include patients in window-of-opportunity setting -
- GLIX1 demonstrated robust, dose-dependent antitumor activity in multiple GBM models, including confirmed evidence of brain penetration and dose-dependent increases in tumor 5hmC -
TEL AVIV, Israel and OSLO, Norway, Nov. 16, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two posters featuring GLIX1 were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting.
